Search 

Simplifying Clinical Research 

Boston Biotech Clinical Research (BBCR) is a strategic clinical innovation organization (SCIO) that offers simplified, customized approaches to planning and conducting clinical research. 
BBCR has a strong knowledge of drug safety, strategic planning and how to maximize the potential of early phase clinical research. 

BBCR helps biotech, pharmaceutical and device companies to deliver capital- and time-efficient clinical development programs – and thereby helps fulfil their product development. 

The innovative approach offered by BBCR facilitates: 
• Strategic clinical plan that, accelerate value creation from the earliest phase of clinical trials 
• Innovative simplified clinical research, using strategies that fully utilize available resources – meeting the requirements of investors, partners and regulators 
• Evidence-based trial strategies, helping to reduce risks and maximize the chances of successful outcomes 
• Design-focused trials that facilitate patients’ recruitment and retention, and cost-effective clinical research

Boston Biotech Clinical Research (BBCR) is a strategic clinical innovation organization (SCIO) that offers simplified, customized approaches to planning and conducting clinical research. BBCR has a strong knowledge of drug safety, strategic planning and how to maximize the potential of early phase clinical research. BBCR helps biotech, pharmaceutical and device companies to deliver capital- and time-efficient clinical development programs – and thereby helps fulfill their product development strategies.

The innovative approach offered by BBCR facilitates:

• Strategic clinical plans that, accelerate value creation from the earliest phase of clinical trials
• Innovative simplified clinical research, using strategies that fully utilize available resources – meeting the requirements of investors, partners and regulators
• Evidence-based trial strategies, helping to reduce risks and maximize the chances of successful outcomes
• Design-focused trials that facilitate patient recruitment and retention, and cost-effective clinical research

Boston Harbor Angels is a group of proven business leaders interested in investing a portion of our assets in high-growth, early-stage companies. Since 2004 we have made investments in companies in medical devices, IT, consumer products, business products, specialty materials, Internet, aviation, etc. We believe we contribute more than money to the companies we fund and welcome the opportunity to work with entrepreneurs who are open to taking advice, yet have the smarts and determination to make their company successful.

Our focus is on early-stage companies, usually looking to raise $250K to $1.5M, where we can fund a portion of the round and syndicate the deal with other angel groups or early-stage venture funds. The company should be close to the commercialization stage and have a clear and defensible competitive advantage. We are looking for capital-efficient businesses that can reach profitability with less than $5M of equity investment and provide at least a tenfold return on the investment within five years.

BHA does not invest as a fund—each of our members makes his or her individual investment decision—but we collaborate in due diligence. We are open to any opportunities that can make a strong business case and can take the position of a lead investor if one of us has strong expertise within our group.

BHA receives 20-30 business summaries each month, out of which we select eight companies to make a personal presentation to our screening committee. The screening committee consists of volunteers from the group. The presentations are 10 minutes long, followed by 30-minute interactive discussion on the business opportunity. We provide our feedback on the strategy, tactics, presentation style, etc. on the spot. Four of the companies are invited to present to the whole group, so as to get members interested. After that, we decide to undertake due diligence concerning the companies before making an investment.

Boston Harbor Angels was founded by Mic Williams (president) in February 2004. Day-to-day operations are managed by Boris Batchvarov (managing director).

There are multiple suppliers and distributors of the organ preservation solutions developed by Drs. Belzer and Southard at the University of Wisconsin. All patents on the formulations used in Belzer UW® Solutions (cold storage and machine perfusion) expired in 2006. Bridge to Life has an exclusive trademark license from the Wisconsin Alumni Research Foundation (WARF) for the trademark Belzer UW®.

In fact, WARF holds an equity position in Bridge to Life Ltd., a WARF startup company. We proudly honor the name of Dr. Belzer and the institution that developed the UW organ preservation solution, which is still the “gold standard” in organ preservation.

In 2008 the Leducq Family Trust established Broadview Ventures, Inc.(Broadview). Broadview’s mission is to accelerate the development of promising technology in cardiovascular and neurovascular disease through targeted investments in and support of early stage ventures.

By making funding available at a critical moment in the development of new technology, the Leducq Family Trust is taking a leadership position in venture philanthropy by finding creative ways to support translational research in order to bring the advancements of science to the care of patients.

Nishant "Nish" Rastogi shares responsibility for the day-to-day operations of Broadview Ventures, including identification and screening of new opportunities, due diligence, negotiation of deal structure, and portfolio company involvement.

Welcome to the Center for Human Reproduction (CHR), a leading fertility center located in New York City. CHR is known as a “fertility center of last resort,” primarily serving patients who have previously failed treatments elsewhere. Among CHR’s areas of special expertise are treatments of “older” ovaries, whether due to advanced female age or premature ovarian aging (POA), immunological problems affecting reproduction, repeated pregnancy loss, endometriosis, polycystic ovary syndrome (PCOS), tubal disease, male factor infertility, etc.

Harnessing the brain’s immune system to fight neurodegeneration.

CereSpir is leading the way with a completely novel approach to Alzheimer’s disease (AD) by reducing inflammation and increasing clearance of tissue debris in the brain as a potential first disease-modifying treatment targeting the very earliest stages of the disease.

CSP-1103, an orally delivered tablet, has undergone Phase 2 testing in people with Mild Cognitive Impairment (MCI). The Company aims to initiate Phase 3 trials in 2015. CSP-1103 is a novel, first-in-class, small molecule microglial modulator that protects neurons and other cells in the brain. CSP-1103 is a novel, first-in-class, small molecule microglial modulator that protects neurons and other cells in the brain.